parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including microglia; strongest in oocytes	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13895

GCNT2 in dopamine neurons, braak+0.05 (p 0.891) → +0.22 (p 0.576)receipt 13903
GCNT2 in microglia, braak+0.08 (p 0.838) → +0.11 (p 0.778)receipt 13902

receipt 13903: GCNT2 in dopamine neurons, braak

power: full sample +0.09 (p 0.728, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.962, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.23, sign flips 3; without severely affected donors +0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GCNT2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13902: GCNT2 in microglia, braak

power: full sample +0.10 (p 0.683, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.827, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.09 (p 0.722, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.26, sign flips 1; without severely affected donors +0.10 (p 0.683, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GCNT2 in microglia.

case closed: nothing better to follow up.

loading the receipts